12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Myalept metreleptin regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11-1 that Bristol-Myers Squibb's Amylin Pharmaceuticals Inc. subsidiary provided substantial evidence that the benefits of Myalept metreleptin exceed the risks in patients with generalized lipodystrophy. However, the panel voted 10-2 that the benefits of metreleptin did not...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >